Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

Rhea-AI Summary

Fate Therapeutics, a clinical-stage biopharmaceutical company focusing on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, announced their participation in the 2024 Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2024, at 3:00 PM ET in New York. The event will be webcasted live and accessible on the Company’s website, with an archived version available post-event.

Positive

• Fate Therapeutics is presenting at a major healthcare conference, indicating increased visibility and potential investor interest.
• The focus on iPSC-derived cellular immunotherapies aligns with current trends in personalized medicine and innovative treatments for cancer and autoimmune diseases.

Negative

• There is no mention of new clinical data or significant advancements, which could be a concern for investors looking for tangible progress.
• The PR does not provide financial updates or projections, leaving some uncertainty about the company's current financial health and future prospects.

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will present at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 3:00 PM ET in New York, New York.

A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com

FAQ

What is Fate Therapeutics presenting at the 2024 Jefferies Global Healthcare Conference?

Fate Therapeutics will present their developments in iPSC-derived cellular immunotherapies for cancer and autoimmune diseases.

When is Fate Therapeutics presenting at the 2024 Jefferies Global Healthcare Conference?

Fate Therapeutics will present on Wednesday, June 5, 2024, at 3:00 PM ET.

Where can I watch the Fate Therapeutics presentation at the 2024 Jefferies Global Healthcare Conference?

The presentation will be webcasted live and accessible in the Investors section of Fate Therapeutics' website, with an archived version available after the event.